A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Patients With Moderate-to-Severe Palmoplantar Pustulosis

Exclusion Criteria

• •Significant improvement of PPP symptoms between screening and baseline (PPPASI decrease ≥ 5).
• •Presence of other forms of psoriasis or inflammatory skin diseases.
• •Active infection or history of serious infection within specified timeframes.
• •Positive for hepatitis B, hepatitis C, or HIV.
• •Active or latent tuberculosis.
• •History of malignancy within 5 years (except certain skin cancers).